Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Mavoglurant

EU orphan designation number: EU/3/12/1046   
Active ingredient: Mavoglurant
Indication: Treatment of fragile X syndrome
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/10/2012 Centralised Orphan - Designation EMA/OD/059/12 (2012)7222 of 10/10/2012
29/08/2014 Centralised Orphan - Change of address